Literature DB >> 29147028

Cancer: Bispecific antibody directs T cells to solid tumours.

Megan Cully.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2017        PMID： 29147028     DOI： 10.1038/nrd.2017.237

Source DB:  PubMed          Journal:  Nat Rev Drug Discov        ISSN： 1474-1776            Impact factor:   84.694


× No keyword cloud information.
  1 in total

1.  An anti-glypican 3/CD3 bispecific T cell-redirecting antibody for treatment of solid tumors.

Authors:  Takahiro Ishiguro; Yuji Sano; Shun-Ichiro Komatsu; Mika Kamata-Sakurai; Akihisa Kaneko; Yasuko Kinoshita; Hirotake Shiraiwa; Yumiko Azuma; Toshiaki Tsunenari; Yoko Kayukawa; Yukiko Sonobe; Natsuki Ono; Kiyoaki Sakata; Toshihiko Fujii; Yoko Miyazaki; Mizuho Noguchi; Mika Endo; Asako Harada; Werner Frings; Etsuko Fujii; Eitaro Nanba; Atsushi Narita; Akihisa Sakamoto; Tetsuya Wakabayashi; Hiroko Konishi; Hiroaki Segawa; Tomoyuki Igawa; Takashi Tsushima; Hironori Mutoh; Yukari Nishito; Mina Takahashi; Lorraine Stewart; Ehab ElGabry; Yoshiki Kawabe; Masaki Ishigai; Shuichi Chiba; Masahiro Aoki; Kunihiro Hattori; Junichi Nezu
Journal:  Sci Transl Med       Date:  2017-10-04       Impact factor: 17.956
  1 in total
  3 in total

1.  High throughput development of TCR-mimic antibody that targets survivin-2B80-88/HLA-A*A24 and its application in a bispecific T-cell engager.

Authors:  Nobuyuki Kurosawa; Yuka Wakata; Kenta Ida; Aki Midorikawa; Masaharu Isobe
Journal:  Sci Rep       Date:  2019-07-08       Impact factor: 4.379

2.  CAR-T "the living drugs", immune checkpoint inhibitors, and precision medicine: a new era of cancer therapy.

Authors:  Delong Liu
Journal:  J Hematol Oncol       Date:  2019-11-08       Impact factor: 17.388

Review 3.  Recent advances and challenges of bispecific antibodies in solid tumors.

Authors:  Yuze Wu; Ming Yi; Shuangli Zhu; Haiyong Wang; Kongming Wu
Journal:  Exp Hematol Oncol       Date:  2021-12-18
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.